METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,590,107 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS In force · Medium confidence UsedRemaining | Curasen Therapeutics, Inc. | In force | Medium confidence | ||
| Application 17/100,758 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS Abandoned Abandoned Jun 20, 2023 | Curasen Therapeutics, Inc. | Abandoned | Abandoned Jun 20, 2023 | ||
| Application 17/770,276 | Methods for Treating Neurological Disorders with ALPHA1A-AR Partial Agonists Abandoned Abandoned Feb 21, 2026 | Curasen Therapeutics, Inc. | Abandoned | Abandoned Feb 21, 2026 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Curasen Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.